JP2016536004A - 乳癌再発の予測 - Google Patents

乳癌再発の予測 Download PDF

Info

Publication number
JP2016536004A
JP2016536004A JP2016542081A JP2016542081A JP2016536004A JP 2016536004 A JP2016536004 A JP 2016536004A JP 2016542081 A JP2016542081 A JP 2016542081A JP 2016542081 A JP2016542081 A JP 2016542081A JP 2016536004 A JP2016536004 A JP 2016536004A
Authority
JP
Japan
Prior art keywords
risk
recurrence
bci
subject
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016542081A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536004A5 (enExample
Inventor
シュナーベル，キャサリン，エー．
スグロイ，デニス，シー．
ツァン，イ
スクローダー，ブロック
エルランダー，マーク，ジー．
Original Assignee
バイオ セラノスティックス，インコーポレイテッド
バイオ セラノスティックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオ セラノスティックス，インコーポレイテッド, バイオ セラノスティックス，インコーポレイテッド filed Critical バイオ セラノスティックス，インコーポレイテッド
Publication of JP2016536004A publication Critical patent/JP2016536004A/ja
Publication of JP2016536004A5 publication Critical patent/JP2016536004A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016542081A 2013-09-11 2014-09-10 乳癌再発の予測 Pending JP2016536004A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361876757P 2013-09-11 2013-09-11
US61/876,757 2013-09-11
PCT/US2014/055041 WO2015038682A1 (en) 2013-09-11 2014-09-10 Predicting breast cancer recurrence

Publications (2)

Publication Number Publication Date
JP2016536004A true JP2016536004A (ja) 2016-11-24
JP2016536004A5 JP2016536004A5 (enExample) 2017-10-19

Family

ID=52666241

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016542081A Pending JP2016536004A (ja) 2013-09-11 2014-09-10 乳癌再発の予測

Country Status (10)

Country Link
US (2) US20150203921A1 (enExample)
EP (1) EP3044335B1 (enExample)
JP (1) JP2016536004A (enExample)
CN (1) CN105722998A (enExample)
BR (1) BR112016005225B1 (enExample)
CA (1) CA2923606A1 (enExample)
ES (1) ES2829912T3 (enExample)
IL (2) IL244554B (enExample)
MX (2) MX2016002938A (enExample)
WO (1) WO2015038682A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
WO2012079059A2 (en) 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis
MX2018005867A (es) 2015-11-13 2018-09-21 Biotheranostics Inc Integracion de las caracteristicas tumorales con el indice de cancer de mama.
MX2021001857A (es) * 2018-08-17 2021-10-13 Genentech Inc Star Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama.
CN112646890B (zh) * 2020-12-29 2024-08-16 郑鸿钧 用于预测早期乳腺癌远处复发风险的多基因检测引物
EP4594533A1 (en) * 2022-09-30 2025-08-06 Biotheranostics, Inc. Biomarker assay to select breast cancer therapy
CN117476246B (zh) * 2023-12-25 2024-04-19 福建大数据一级开发有限公司 基于多类型复发事件的患者生存分析方法、介质及装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012079059A2 (en) * 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
CA2350502C (en) 1998-11-13 2009-01-27 Pro Duct Health, Inc. Devices and methods to identify ductal orifices during nipple aspiration
US6794141B2 (en) 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
AU2004274973A1 (en) 2003-09-19 2005-03-31 Aviaradx, Inc. Predicting breast cancer treatment outcome
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
CA2698569A1 (en) * 2007-09-06 2009-09-03 Mark G. Erlander Tumor grading and cancer prognosis
CN105821125A (zh) * 2010-03-31 2016-08-03 斯维丹诊断有限责任公司 用于内分泌治疗下的乳腺癌复发预测的方法
CA2854805C (en) * 2011-11-08 2021-04-27 Genomic Health, Inc. Method of predicting breast cancer prognosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012079059A2 (en) * 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MA, XIAO-JUN ET AL.: ""A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early s", CLIN. CANCER RES., vol. 14, JPN6018022583, 2008, pages 2601 - 2608, ISSN: 0003964047 *
ZHANG, YI ET AL.: ""Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at ris", CLIN. CANCER RES., vol. 19, JPN6018022580, 2013, pages 4196 - 4205, ISSN: 0003964046 *

Also Published As

Publication number Publication date
IL244554A0 (en) 2016-04-21
MX2021002014A (es) 2021-04-28
EP3044335A1 (en) 2016-07-20
BR112016005225A2 (enExample) 2017-08-01
EP3044335A4 (en) 2017-04-19
BR112016005225B1 (pt) 2023-11-14
MX2016002938A (es) 2016-07-26
US20220186317A1 (en) 2022-06-16
EP3044335B1 (en) 2020-09-09
IL276505B (en) 2022-03-01
CN105722998A (zh) 2016-06-29
WO2015038682A1 (en) 2015-03-19
ES2829912T3 (es) 2021-06-02
IL276505A (en) 2020-09-30
IL244554B (en) 2020-08-31
CA2923606A1 (en) 2015-03-19
US20150203921A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
US12460265B2 (en) Post-treatment breast cancer prognosis
US20220186317A1 (en) Predicting breast cancer recurrence
CN102395682B (zh) 肿瘤分级和癌症预后
EP2121988B1 (en) Prostate cancer survival and recurrence
JP2011525106A (ja) 瀰漫性ｂ大細胞型リンパ腫のマーカーおよびその使用方法
US9721067B2 (en) Accelerated progression relapse test
WO2005001138A2 (en) Breast cancer survival and recurrence
KR102376220B1 (ko) 전립선암에서 후기 임상적 종점을 평가하기 위한 알고리즘 및 방법
US20180051342A1 (en) Prostate cancer survival and recurrence
EP2872651B1 (en) Gene expression profiling using 5 genes to predict prognosis in breast cancer
AU2014318859A1 (en) Predicting breast cancer recurrence
HK1197803A (en) Post-treatment breast cancer prognosis

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20161115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170908

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190129